welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy
study id #: NCT01098708
condition: Duchenne Muscular Dystrophy
Many therapeutic trials in DMD exclude non-ambulatory boys and men. Rate of progression in these non-ambulatory patients has been studied but consensus has not been reached for what measures are most reliable and reproducible. Furthermore, any treatment trial would be expected to demonstrate improved function and improvement in quality of life. Therefore, function, strength, and quality of life must be understood and standardized. While the goal of this proposal is to standardize clinical outcomes for therapeutic trials, careful understanding of the progression of DMD in non ambulatory boys may also lead to better medical treatment.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: March 2010
estimated completion: November 2013
size / enrollment: 50
study description: For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year.
Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years.
Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
- Dystrophin gene mutations that predispose to early onset cardiomyopathy [ Time Frame: 3 years ]
• For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year.
• Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years.
• Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
For Non-ambulatory study, the inability to understand and cooperate with the testing would exclude a subject.
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
Orthopedic and surgical management of the patient with Duchenne muscular dystrophyOrthopedic care is an important aspect o...
The time to and determinants of first fractures in boys with Duchenne muscular dystrophyBoys with vertebral fractures (VF) ident...
Open Label Extension Study of HT-100 in Patients With DMDThis study is designed to provide 6-mont...
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)The aim of this Phase III study was to a...
Skeletal muscle homeostasis in duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategyMuscular dystrophies are a group of gene...